Priothera
PrivateLast Round
Series B
Feb 3, 2026
Total Funding Raised
$98.27M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Priothera is a biotechnology company that develops S1P receptor modulators to improve outcomes for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Priothera Comparables
Compare Priothera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bristol Myers Squibb | 69% | |
| MaaT Pharma | 68% | |
| Incyte Corporation | 67% |
Priothera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 3, 2026 | ||||
| Grant | Jul 11, 2025 | ||||
| Grant | Jun 24, 2024 | ||||
| Debt | Apr 4, 2022 | ||||
| Debt | Feb 23, 2022 | ||||
Series A | Oct 12, 2020 |
Priothera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 4see ventures | Series B |
| Fountain Healthcare Partners | Series B, Series A |
| HealthCap | Series B, Series A |
| European Investment Bank Group | Debt |
| Tekla Capital Management | Series A |
| Earlybird Venture Capital | Series B, Series A |
| European Union | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 35% MoM.
- Feb 3, 2026
$39M round led by 4see ventures
Recent news
Latest coverage and updates
- hiresSep 3, 2026
Priothera Ltd. hired Nigel Clark as Chief Business Officer on Sep 3rd '26.
Priothera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Priothera's valuation, stock price, and market status.
Is Priothera a public or private company?
Priothera is a private company.
What is the current stock price of Priothera?
Priothera is a private company with no public stock price. No recent secondary market data is available.
How much is Priothera worth (valuation)?
Valuation information for Priothera is not publicly available.
Can I buy Priothera stock?
Priothera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Priothera's last funding round?
Priothera's most recent funding round was Grant on June 24, 2025.
Who are the main investors in Priothera?
Key investors in Priothera include Bpifrance, Fountain Healthcare Partners, HealthCap, Bpifrance.
Will Priothera IPO soon?
No public IPO plans have been announced for Priothera.
How can I track Priothera secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Priothera's secondary market activity and sign up for updates.